Results 171 to 180 of about 7,117 (221)

Acalabrutinib

Reactions Weekly, 2021
openaire   +2 more sources

A real-world comparative analysis of cardiovascular (CV) safety and time to next treatment (TTNT) with acalabrutinib versus ibrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Journal of Clinical Oncology
e23280 Background: Bruton tyrosine kinase inhibitors (BTKis) are standard of care in CLL/SLL. However, BTKis, especially ibrutinib, are associated with CV toxicities that can affect the relative dose intensity and duration of therapy.
D. Ermann, George Dranitsaris, S. Blau, A. Peevyhouse, H. Neuhalfen, S. Wahlstrom, Samantha L. Thompson, A. Teschemaker, Vikram Shetty, M. Narkhede   +9 more
semanticscholar   +1 more source

A new stability indicating RP-HPLC method for the estimation of Acalabrutinib

Research Journal of Pharmacy and Technology
Acalabrutinib is an anti-cancer drug used for metastatic prostate cancer treatment. A new stability indicating RP-HPLC method was developed and validated for the determination of Acalabrutinib in tablets. Shimadzu HPLC Model no. iSeries 2050C 3D with Lab
Hema Hema, Naresh Panigrahi
semanticscholar   +1 more source

Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up

Blood
Introduction: The introduction of the Bruton tyrosine kinase inhibitor acalabrutinib combined with bendamustine and rituximab (ABR) as first-line (1L) therapy for mantle cell lymphoma (MCL) in older patients (pts) is reshaping the approach to ...
Michael Wang, J. Paludo, J. S. de Holanda Farias, D. Villa, Cecily Forsyth, E. John, Menglu Che, Harneet Arora, Craig Delury, Victoria Otero, Yuqin Song   +10 more
semanticscholar   +1 more source

Ibrutinib/prednisone/acalabrutinib

Reactions Weekly
openaire   +2 more sources

Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial

Blood
In mantle cell lymphoma (MCL), clinical progression of disease within 24 months of treatment initiation (POD24) is associated with poorer outcomes. Acalabrutinib plus bendamustine-rituximab (ABR) has been approved for patients with treatment-naive (
C. Cheah, S. Spurgeon, Sung-Soo Yoon, Mélina Boutin, E. González Barca, K. Bouabdallah, E. John, Tatjana Krautloher, Victoria Otero, Brad S. Kahl   +9 more
semanticscholar   +1 more source

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

Blood
Introduction: While Bruton tyrosine kinase (BTK) inhibitors are a mainstay of treatment for B-cell malignancies, their use can be limited by adverse events (AEs).
M. Shadman, I. Flinn, M. Levy, Steven Papish, John M. Burke, J. Misleh, Jennifer Cultrera, H. Yimer, E. Kingsley, Charles M. Farber, J. D'Olimpio, Nan Sun, A. Idoine, J. Sharman   +13 more
semanticscholar   +1 more source

Simultaneous Presentation of Cutaneous Waldenström Macroglobulinemia and Acalabrutinib-Related Toxicity.

American journal of dermatopathology
Waldenström macroglobulinemia (WM) is a rare B-cell lymphoplasmacytic lymphoma associated with clonal IgM gammopathy, comprising 1%-2% of hematological malignancies.
Tania Platero-Portillo, Vicki Mercado-Evans, Nisha S Ramani, B. Krishnan   +3 more
semanticscholar   +1 more source

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Blood
Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated clinical efficacy in treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Jing-Zhou Hou, Rushir J. Choksi, G. Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Rhys Williams, D. Ermann   +10 more
semanticscholar   +1 more source

Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison

Blood
Background: Bruton's tyrosine kinase inhibitors (BTKis), like acalabrutinib and zanubrutinib, have revolutionized the treatment of chronic lymphocytic leukemia (CLL).
Lay She Ng, Alice He, Yone Phar Lin, Vyom Patel, Martin Cuevas, W. Ng, Oksana Karpov, Utpal Dave   +7 more
semanticscholar   +1 more source